Bioventus

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Concept,Med,Industry,On,Medicine,Factory.,Worker,Use,Control,Panel

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Stock Movers

COHR

COIN

GRAB

HOOD

HSAI

METC

RDDT

SATS

XPEV

Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday

YUMC

Equities

Eurozone

Commodities

Markets

BNOX

VMEO

VRCA

ZVSA

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Bioventus Inc

BRAVURA SOLUTIONS LTD by Bravura Solutions Ltd.

Bravura Solutions Ltd

BMO ASIA USD INVST GR by BMO Asia USD Investment Grade Bond ETF

Press Releases

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Bioventus Reports Third Quarter Financial Results

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Bioventus Reports First Quarter Financial Results

Align Technology

Avanos Medical

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Cuprina Holdings (Cayman) Limited - Ordinary shares

Cuprina Holdings (Cayman)

Embecta

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Technologies

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Canaccord Genuity

JP Morgan

Craig-Hallum

Goldman Sachs

Comments

Bioventus

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell